Publication | Closed Access

EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers

Cell-based Drug DeliveryBreast OncologyTriple-negative Breast CancersMedicineEgfr-targeted ImmunoliposomesImmunologyBreast CancerSelective Delivery SystemTumor TargetingPharmacologyCancer GrowthTumor Microenvironment